SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 2006; 55: 18329.
  • 2
    Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 22532.
  • 3
    Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: The Kidney, 6th edn, ed. BrennerBM. Philadelphia, PA: W.B. Saunders, 2000; 173173.
  • 4
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 57781.
  • 5
    Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996; 335: 163642.
  • 6
    Gæde P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 61722.
  • 7
    Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 2539.
  • 8
    Glucophage Prescribing Information. Available at http://www.fda.gov/CDER/foi/label/2000/21202lbl.pdf (last accessed 10 November 2008).
  • 9
    Micronase (glyburide) Tablets Prescribing Information. Available at http://media.pfizer.com/files/products/uspi_micronase.pdf (last accessed 2 November 2008).
  • 10
    Glipizide Extended Release Tablets Prescribing Information. Available at http://media.pfizer.com/files/products/uspi_glipizide.pdf (last accessed 2 November 2008).
  • 11
    Precose (acarbose tablets) Prescribing Information. Available at http://www.univgraph.com/bayer/inserts/precose.pdf (last accessed 10 November 2008).
  • 12
    Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 31727.
  • 13
    Byetta (exenatide injection) Prescribing Information. Available at http://pi.lilly.com/us/byetta-pi.pdf (last accessed 2 November 2008).
  • 14
    Holst JJ. Enteroglucagon. Annu Rev Physiol 1997; 59: 25771.
  • 15
    Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 2003; 17: 93102.
  • 16
    Nauck MA, Meier JJ, Creutzfeldt W. Incretins and their analogues as new antidiabetic agents. Drug News Perspect 2003; 16: 41322.
  • 17
    Nauck MA, Hompesch M, Filipczak R, Le TDT, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114: 41723.
  • 18
    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 213157.
  • 19
    Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thøgersen H, Wilken M, Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 16649.
  • 20
    Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195202.
  • 21
    Helleberg H, Malm-Erjefält M, Bjørnsdottir I, Larsen US, Oosterhuis B, Van Lier JJ, Zdravkovic M. Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects. Diabetes 2008; 57 (Suppl. 1): A581 (Abstract 2107-PO).
  • 22
    Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E74552.
  • 23
    Raun K, Von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting GLP-1 analogue, reduces body weight and food intake in obese candy fed rats while a DPP-IV inhibitor, LAF237, does not. Diabetes 2007; 56: 815.
  • 24
    Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, Westergaard L, Deacon CF, Knudsen LB. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002; 451: 21725.
  • 25
    Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB. GLP-1 derivative liraglutide in rats with b-cell deficiencies: influence of metabolic state on b-cell mass dynamics. Br J Pharmacol 2003; 140: 12332.
  • 26
    Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB, Petersen JS. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005; 330: 57784.
  • 27
    Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, Nielsen JH, Møldrup A. Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006; 188: 48192.
  • 28
    Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 47381.
  • 29
    Vilsbøll T, Zdravkovic M, Le Thi T, Krarup T, Schmitz O, Courreges J-P, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a once-daily GLP-1 analog, monotherapy significantly improves glycaemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007; 30: 160810.
  • 30
    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 4249.
  • 31
    Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, Galecki A, Halter JB. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52: 178691.
  • 32
    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long-acting GLP-1 derivative, liraglutide (NN2211), markedly improves 24-h glycaemia, alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 118794.
  • 33
    Madsbad S, Brock B, Perrild H, Lervang HH, Kolendorf K, Krarup T, Schmitz O, Le-Thi T, Zdravkovic M, Vilsboll T. Liraglutide significantly improves first-phase insulin secretion and maximal beta-cell secretory capacity. Diabetologia 2006; 49 (Suppl. 1): A0004.
  • 34
    Vilsbøll T, Brock P, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 1526.
  • 35
    Courreges JP, Zdravkovic M, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a once-daily human glucagon-like peptide-1 analogue, shows beneficial effects on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008; 25: 112931.
  • 36
    Committee for Medicinal Products for Human Use. Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function. London: European Medicines Agency, 2004. Available at http://www.tga.gov.au/DOCS/pdf/euguide/ewp/022502en.pdf (last accessed 4 June 2009).
  • 37
    Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study design, Data Analysis, and Impact on Dosing and Labeling. Rockville, MD: US Department of Health and Human Services Food and Drug Administration, 1998. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf (last accessed 4 June 2009).
  • 38
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 39
    Runge S, Mayerle J, Warnke C, Robinson D, Roser M, Felix SB, Friesecke S. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab 2008; 10: 913.
  • 40
    Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006; 7: 36774.
  • 41
    Flint A, Nazzal K, Jagielski P, Segel S, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. Diabetes 2007; 56 (Suppl. 1): A145.